#None #Class Action #Faruqi & Faruqi #Ardelyx

Upcoming Deadline for Ardelyx Investors

As the deadline of November 16, 2026, approaches, investors in Ardelyx, Inc. should take notice. The leading national securities law firm, Faruqi & Faruqi, LLP, has publicly announced an ongoing investigation into potential claims against Ardelyx (NASDAQ: ARDX) related to a securities class action lawsuit. Those who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, are particularly encouraged to explore their options now.

Background on the Class Action Lawsuit

The investigation led by Faruqi & Faruqi arises from allegations that Ardelyx and its executives misled investors regarding the company's commercial performance and growth potential for its products, XPHOZAH and IBSRELA. The complaints indicate that Ardelyx failed to adequately disclose critical information about challenges in accessing payer-related reimbursement and the overall commercial scaling of their products.

On August 6, 2026, Ardelyx disclosed a significant reduction in its expected revenue for IBSRELA for the full year. Alongside this, the company withdrew long-term revenue guidance for XPHOZAH. This marked a turning point for investors, as Ardelyx management attributed this revenue downgrade to increased restrictions by payers, which hindered patient access and resulted in delays in prescription fulfillment. Consequently, Ardelyx's stock plummeted from a closing price of $4.87 on August 6 to $4.00 on August 7, reflecting an 18% drop in just one day. Such movements might signal larger underlying issues within the company.

Who Can Participate?

Faruqi & Faruqi stresses that any investor who acquired Ardelyx securities during the stipulated period and suffered losses is eligible to seek participation in the class action. The lead plaintiff will primarily represent the class, ensuring that the litigation is managed effectively. However, investors can choose to remain as part of the class without taking an active role. It’s essential to note that a lawyer can be hired for guidance through the process, and this does not impact the ability to recover losses from the case.

Call to Action

Faruqi & Faruqi’s partner, James (Josh) Wilson, has made an appeal to affected investors urging them to come forward and discuss their legal rights and options. Interested parties can contact the firm directly at the numbers provided—877-247-4292 or 212-983-9330 (Ext. 1310). Furthermore, all inquiries are confidential, providing those who suffered losses a safe space to explore their possibilities.

Importance of Timely Action

The importance of acting swiftly cannot be overstated; the lead plaintiff application must be filed by the deadline of November 16, 2026. Failure to do so can result in missing the opportunity to recover losses from potential legal proceedings. Thus, it is critical for investors to evaluate their standing and take appropriate action before the due date.

Conclusion

The upcoming deadline is a crucial moment for investors in Ardelyx, Inc. as they grapple with the implications of significant changes in corporate governance and financial outlook. With Faruqi & Faruqi leading the charge for accountability and investor rights, now is the time for those affected to make their voices heard and explore their potential claims in this legal landscape. For further information and guidance on how to proceed, visit Faruqi & Faruqi's dedicated page on Ardelyx or reach out directly for a free consultation on potential claims.